GSK India reported strong Q1 results: Revenue up 15% to INR 924 Cr, PAT up 24% to INR 253 Cr.

Growth fueled by core portfolio, innovative oncology, and vaccines.

Upcoming launches include Blenrep and Arexvy.

No comments yet. Be the first.

More from GlaxoSmithKline Pharmaceuticals Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.